[Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
The possibility of using tobramycin (Tb) in combination with P. aeruginosa polyvalent corpuscular vaccine (PaPCV) or pyocyanosis hyperimmune plasma (PHP) for the treatment of P. aeruginosa sepsis was experimentally studied. The combined use of Tb and PHP, administered in amounts corresponding to ED50 of each preparation used separately, ensured the survival of 90% of the infected mice, and the injected of PaPCV with ED50 of the antibiotic ensured the survival of 73% of the experimental animals. The combined use of Tb and the two immuno-preparations (PaPCV and PHP) for the treatment of P. aeruginosa infection proved to be more effective than their separate administrations.
D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002056:Burns / Q000150:complications / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007116:Immunization, Passive; D051379:Mice; D011552:Pseudomonas Infections / Q000401:mortality / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D014031:Tobramycin / Q000627:therapeutic use*
D001428:Bacterial Vaccines; D014031:Tobramycin
Eksperimental'noe obosnovanie kombinirovannogo primeneniia tobramitsina i immunopreparatov dlia lecheniia ostroĭ sinegnoĭnoĭ infektsii.